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Atherosclerosis Compendium
Abstract: Advances in atherosclerosis imaging technology and research have provided a range of diagnostic tools to 
characterize high-risk plaque in vivo; however, these important vascular imaging methods additionally promise 
great scientific and translational applications beyond this quest. When combined with conventional anatomic- and 
hemodynamic-based assessments of disease severity, cross-sectional multimodal imaging incorporating molecular 
probes and other novel noninvasive techniques can add detailed interrogation of plaque composition, activity, and overall 
disease burden. In the catheterization laboratory, intravascular imaging provides unparalleled access to the world 
beneath the plaque surface, allowing tissue characterization and measurement of cap thickness with micrometer spatial 
resolution. Atherosclerosis imaging captures key data that reveal snapshots into underlying biology, which can test our 
understanding of fundamental research questions and shape our approach toward patient management. Imaging can 
also be used to quantify response to therapeutic interventions and ultimately help predict cardiovascular risk. Although 
there are undeniable barriers to clinical translation, many of these hold-ups might soon be surpassed by rapidly evolving 
innovations to improve image acquisition, coregistration, motion correction, and reduce radiation exposure. This article 
provides a comprehensive review of current and experimental atherosclerosis imaging methods and their uses in research 
and potential for translation to the clinic.  (Circ Res. 2016;118:750-769. DOI: 10.1161/CIRCRESAHA.115.306247.)
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For many, atherosclerosis occurs as an indolent process arising throughout adult life because of multiple patho-
logical changes triggering lipoprotein dysregulation and im-
mune-cell activation at vulnerable points within the arterial 
system.1 Pathologically, this manifests in a series of histologi-
cally and structurally distinct lesion types with varying com-
plexity and propensity to instigate an acute clinical event.2 As 
most individuals with atherosclerosis will never experience 
overt clinical symptoms related to their disease, it is, therefore, 
not surprising that >50% of those who die suddenly because 
of coronary heart disease lack prior warning of their condi-
tion.3 This tip-of-the-iceberg scenario presents a tremendous 
diagnostic challenge, underpinning the rising global health 
burden of cardiovascular disease (CVD). Although preven-
tative strategies and improved treatments adopted mostly by 
wealthy countries have reduced global age-standardized death 
rates because of ischemic heart disease and ischemic stroke by 
19.5% and 26.6%, respectively, since 1990, these remain the 
top 2 causes of death worldwide, with increasing prevalence 
in many lower- and middle-income countries and among the 
growing aging population.4
Well-trodden CVD risk-assessment algorithms and diag-
nostic pathways have reasonable sensitivity and specificity to 
identify individuals deemed to be at increased risk of future 
clinical events, and those with hemodynamically significant 
intraluminal stenoses that might benefit from a treatment 
strategy including revascularization. However, of the many 
available clinical methods used to diagnose atherosclerosis, 
none can accurately foresee the complex exchange of cellu-
lar, molecular, and biomechanical factors heralding sudden 
symptomatic plaque disruption and its downstream sequelae. 
Thus, there is a need to focus on emerging atherosclerosis 
imaging platforms that allow more accurate visualization of 
culprit pathological processes than standard techniques and to 
develop these tools to help refine risk assessment models and 
guide therapy.
Current Tools and Techniques in the Pipeline
Atherosclerosis imaging encompasses an armamentarium 
of established and experimental radiological methods and 
modalities. Broadly, these techniques can be used to detect 
anatomic and physiological consequences of long-standing 
atherosclerosis, to provide detail on plaque composition and 
molecular activity, and to estimate biomechanical stresses 
acting within the arterial system (Figure 1). Together, these 
methods provide measures of disease severity, which are in-
dispensable to everyday clinical practice and cardiovascular 
research.
Anatomic Imaging
Contrast luminography is the gold-standard anatomic athero-
sclerosis imaging technique. For diagnosis of coronary artery 
disease (CAD), invasive angiography is most often performed; 
this involves selective intubation of the coronary ostia with a 
preshaped catheter introduced via a peripheral arterial sheath, 
used to inject radio-opaque contrast under x-ray fluoroscopy. 
The high-diagnostic accuracy afforded by superior spatial 
(0.1–0.2 mm) and temporal (10 ms) resolution is unmatched 
by noninvasive techniques. Hence, invasive angiography re-
mains the best anatomic reference test to determine the sever-
ity of coronary luminal obstruction and is commonly used to 
guide clinical management, particularly, when contemplating 
revascularization. However, the overall low diagnostic yield 
of elective coronary angiography supports initial noninvasive 
testing and a gate-keeper approach.6,7 Noninvasive angiogra-
phy is possible when using coronary computed tomographic 
angiography (CCTA) or magnetic resonance angiography 
(MRA) combined with ECG-gating to account for cardiac 
movement. CCTA is preferred over MRA for anatomic coro-
nary imaging, although MRA is commonly used to evaluate 
anomalous coronary vessels in children or young women to 
avoid radiation exposure. MRA is best-suited for imaging 
large, static vessels such as the carotid arteries, peripheral ar-
teries or aorta.
Coronary Computed Tomographic Angiography
Multidetector CCTA is a useful first-line diagnostic test for 
appropriately selected patients with symptoms of angina and 
a low-to-moderate pretest probability of CAD. In this context, 
CCTA has excellent negative predictive value, providing a re-
liable means to exclude CAD when the clinical diagnosis is 
doubtful.8 Although precise quantification of anatomic steno-
sis severity in patients with established CAD can be challeng-
ing owing to image artefacts created by coronary calcification, 
CCTA is nonetheless an accurate test with good sensitivity 
to detect anatomically significant CAD when compared with 
invasive angiography in large, prospective, multicenter tri-
als.9,10 CCTA is often performed in conjunction with coronary 
artery calcification (CAC) imaging, a risk stratification tool 
that gives an overall estimate of disease burden and risk of 
future events.11
Current evidence does not support the use of CCTA over 
clinical risk±CAC scores in asymptomatic patients12; however, 
Nonstandard Abbreviations and Acronyms
ACS acute coronary syndrome
CAC coronary artery calcium
CAD coronary artery disease
CCTA coronary computed tomographic angiography
CVD cardiovascular disease
FDG fluorodeoxyglucose
FFR fractional flow reserve
IVUS intravascular ultrasound
MI myocardial infarction
MRA magnetic resonance angiography
NaF sodium fluoride
NIRF near-infrared fluoroscopy
NIRS near infrared spectroscopy
OCT optical coherence tomography
PCI percutaneous coronary intervention
PET positron emission tomography
SPECT single-photon emission computed tomography
TCFA thin-cap fibroatheroma
VH-IVUS virtual histology intravascular ultrasound
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CCTA does add significant diagnostic benefit when added to 
standard care for patients with suspected angina and might 
lead to changes in management that improve long-term sur-
vival in this group.13 It has also been shown to be superior to 
noninvasive functional testing for detection of angiographical-
ly significant coronary stenosis in patients with CAC <400.14,15 
When there is a high pretest probability of CAD or raised 
CAC score, diagnostic x-ray angiography is often preferred 
first-line over CCTA and other noninvasive tests. Among the 
growing list of other clinical indications for anatomic CCTA 
assessment are to improve early clinical decision making for 
patients with acute chest pain in the emergency department, 
as an adjunct to invasive angiography when planning complex 
percutaneous intervention, for detection of in-stent restenosis; 
to check patency of coronary artery bypass grafts; to exclude 
CAD as a cause of left ventricular dysfunction, or before car-
diac valve surgery; and to understand the 3D anatomic rela-
tionship of an anomalous coronary artery to its surrounding 
structures.16,17
The new generations of computed tomography (CT) scan-
ners with larger detector arrays, more detector rows, and du-
al-source systems offer high-quality CCTA images with less 
noise, less artifact, and at lower radiation doses compared with 
earlier models. The spatial resolution of CCTA in the clinical 
setting is roughly 0.5 to 0.6 mm. Depending on the gantry ro-
tation time, and whether a dual-source scanner or single-heart 
beat acquisition is used, the temporal resolution varies from 
66 to 210 ms. Because of improved temporal resolution, good 
Figure 1. Multimodal approach to atherosclerosis imaging. A representative illustration of current and emerging atherosclerosis 
imaging modalities. Each modality offers unique measurements of disease severity. Together, this information can be used to determine 
anatomic and hemodynamic consequences of atherosclerosis, complimented by detail on plaque composition, overall disease 
burden, and current metabolic activity acting within an individual patient. A, X-ray angiography showing multiple right coronary artery 
atherosclerotic lesions (arrows) resulting in significant luminal narrowing; B, virtual histology intravascular ultrasound (VH-IVUS) 
demonstrating coronary plaque with high content of necrotic core (red), as well as dense calcium (white) and fibro-fatty regions (dark/
light green); C, Computed tomographic (CT) angiography showing noncalcified plaque in the left anterior descending artery with positive 
remodeling (dashed line); D, single-photon emission computed tomography (SPECT) myocardial perfusion scan with stress-induced 
perfusion defect (arrow); E, 3D volume rendered CT whole-heart image; F, optical coherence tomography (OCT) image of a coronary 
plaque showing lipid (*), characterized as signal-poor regions with poorly demarcated borders; G, OCT image of a lipid-rich coronary 
plaque displaying thin overlying fibrous cap (arrow), indicative of thin-cap fibroatheroma; H, Fused 18F-NaF positron emission tomography 
(PET)–CT image showing high left anterior descending artery tracer uptake (arrow) revealing active plaque microcalcification; I, 3-T 
magnetic resonance (MR) contrast-angiography performed with dual ECG and respiratory navigator gating showing clear delineation of 
the proximal left-sided coronary vessels. Panel H adapted from Joshi et al.5
 at UNIV OF EDINBURGH on April 26, 2016http://circres.ahajournals.org/Downloaded from 
Tarkin et al  Imaging Atherosclerosis  753
quality images can even be obtained using prospective ECG-
triggering in some patients with an elevated heart rate or ar-
rhythmia, resulting in significantly reduced radiation exposure 
compared with retrospective scanning.18 Diagnostic accuracy 
of CCTA when performed in patients with high CAC might 
also be enhanced by using calcium subtraction methods.19
Magnetic Resonance Angiography
Although 2D-Doppler ultrasound is typically the most acces-
sible first-line test to assess for carotid artery disease in patients 
with recent stroke or transient ischemic attack, MRA is also 
used routinely for this purpose. Compared with CT, MRI has 
superior soft-tissue characterization and lacks ionizing radiation. 
However, in the coronary circulation, obtaining good-quality 
MRA images is challenging because of motion artefacts aris-
ing during prolonged acquisition time and difficulties achieving 
satisfactory contrast-to-noise ratio, spatial resolution, and volu-
metric coverage. It is, therefore, not currently recommended for 
routine clinical use. Despite these challenges, coronary MRA 
is a rapidly developing modality, and with recent technological 
improvements, can provide reliable imaging of the proximal and 
midvessels. These advances include free-breathing 3D whole-
heart acquisition with ECG-gating and navigator respiratory mo-
tion correction, high-field magnetic resonance (MR), 32-channel 
coils with high parallel imaging to accelerate acquisition, T1/T2 
spin preparations, and different pulsed sequences to increase sig-
nal/contrast-to-noise ratios.20,21 When using noncontrast bright-
blood techniques for coronary MRA, which rely on the high T2/
T1 ratio of blood to act as an intrinsic contrast agent, the need 
for potentially nephrotoxic contrast agents can be avoided.
At 1.5 T, whole-heart MRA can identify coronary steno-
ses >50% with reasonable certainty22,23 and identify left main 
stem and three-vessel CAD in 94%.24 Moreover, significantly 
improved diagnostic accuracy has been reported with 3T con-
trast-enhanced whole-heart MRA when compared with x-ray 
angiography in a single center.25 Absence of significant steno-
sis on coronary MRA has also been associated with a low risk 
of subsequent cardiac events when monitored over 2 years.26 
In the future, when scanning patients with suspected CAD, 
integration of coronary MRA with other MR functionalities 
could potentially provide a comprehensive evaluation of coro-
nary anatomy, ventricular wall motion, myocardial perfusion, 
viability, and scarring.
Functional Imaging
For patients with persistent angina despite medical therapy, 
a diagnostic strategy that incorporates functional testing over 
anatomic assessment alone results in overall better symptom 
control and less invasive procedures.27 This is in part due to the 
fact that percentage luminal stenosis does not reliably correlate 
with hemodynamic obstruction or ischemic burden. However, 
while detection of flow-limiting CAD resulting in myocardial 
ischemia relates an adverse prognosis, studies evaluating the 
effects of ischemia reduction after percutaneous coronary in-
tervention (PCI) for stable angina have consistently failed to 
show significant reduction in myocardial infarction (MI) or 
mortality. This finding indicates that functional stenosis sever-
ity might serve as a marker of overall disease burden rather 
than the direct cause of most future clinical events. Diffuse 
atherosclerosis with associated microcirculatory dysfunction 
may additionally contribute to increased risk.28
Hemodynamically significant CAD can be determined 
noninvasively with stress imaging or by pressure-wire as-
sessment during invasive angiography, although these tests 
are often underused before elective PCI.29 For functional 
assessment, exercise is either performed before imaging 
or simulated pharmacologically with adenosine or another 
stress-inducing agent. Noninvasive functional imaging mo-
dalities include stress echocardiography, cardiac MR with 
stress perfusion, and nuclear myocardial perfusion scanning 
with single photon energy computed tomography (SPECT) 
or positron emission tomography (PET); 18F-flurpiridaz is a 
promising novel PET perfusion tracer currently being evalu-
ated in phase 3 clinical trials.30 When comparing these meth-
ods, there are advantages and limitations to each, but they are 
generally equally effective and selection is typically guided 
by local experience and availability. Fractional flow reserve 
(FFR) is the most popular invasive functional method, which 
provides a reliable pressure-based marker of relative coronary 
flow reserve obtained during maximum pharmacological hy-
peremia, which is comparable with absolute myocardial blood 
flow measured by quantitative PET. However, in 1 study, 
>40% of vessels reported as FFR positive (<0.80) had nor-
mal or only mildly reduced coronary flow capacity indicat-
ing that significant myocardial ischemia was unlikely in these 
patients.31 CT perfusion is another emerging technique, which 
if combined with CCTA has reasonable accuracy when evalu-
ated against SPECT, FFR, and MR perfusion.32–34 First pass 
MRI perfusion imaging might also be feasible using dynamic 
nuclear polarization with compounds, such as 13C urea, which 
has the potential to increase signal-to-noise ratio by >10 000-
fold compared with thermally polarized spins.35
Imaging Plaque Morphology and Composition
Beyond conventional anatomic and hemodynamic assess-
ments of lesion severity, detailed plaque characterization can 
be obtained when imaging the vessel wall. Data from autopsy 
studies performed in patients with CAD who died suddenly 
provide the histopathologic basis for high-risk plaque identifi-
cation and have paved the way for so-called vulnerable plaque 
imaging.36 From this work, we know that the most common 
underlying plaque morphology leading to MI comprises a thin 
ruptured fibrous cap with heavy macrophage infiltration and 
few smooth muscle cells, large necrotic core and overlying in-
traluminal thrombosis. Intimal neovascularization is a source 
of intraplaque hemorrhage, which contributes to increased 
risk of plaque rupture.37 Plaque erosion occurs in 30% to 35% 
of sudden coronary death cases, and thrombi attributed to cal-
cified nodules in 2% to 7%.38
The thin-cap (<65 μm) fibroatheroma (TCFA) bears close 
resemblance to ruptured plaque but lacks luminal thrombosis 
and is, therefore, regarded as the most likely precursor lesion 
to plaque rupture. Indeed, cap thickness is the best histologi-
cal discriminator of coronary plaque type, followed by mac-
rophage infiltration and necrotic core.39 The histopathologic 
appearance of recently symptomatic carotid plaques is similar 
to culprit coronary lesions,40 although cap thickness seems 
less important.41 As most rupture-prone coronary plaques 
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occur in a limited, focal distribution, clustered mainly within 
the proximal coronary vasculature,42 both invasive and non-
invasive plaque characterization is feasible. Thin-cap, large 
necrotic core, positive remodeling, microcalcification, and 
neovascularization are among the list of recognized high-risk 
coronary plaque features detectable in vivo; however, the role 
of high-risk plaque imaging in routine clinical practice has yet 
to be determined.
Intravascular Coronary Imaging
Intravascular coronary imaging with ultrasound (IVUS), opti-
cal coherence tomography (OCT), and near infrared-spectros-
copy (NIRS) can provide detailed information about coronary 
plaque composition in patients undergoing invasive angiogra-
phy. An IVUS catheter, constructed from either an electronic 
phased array or single-element design, generates sound waves 
in the 20 to 60 MHz range because of high-speed oscillatory 
movement of a piezoelectronic transducer. Gray-scale IVUS 
has limited ability to differentiate individual plaque compo-
nents, but spectral analysis of the backscattered radiofrequen-
cy data with, for example, virtual histology (VH)-IVUS can 
be used to detect necrotic core, dense calcium, fibrous, and fi-
brofatty plaque with reasonable accuracy.43 However, because 
of increased noise and artifacts, image interpretation can be 
difficult; furthermore, IVUS has insufficient spatial resolution 
to reliably and reproducibly detect thin fibrous cap.44
OCT uses near infrared light (1.3 μm wavelength) emit-
ted through a fiberoptic wire with rotating lens to achieve 
exceptionally high spatial resolution (10–15 μm), providing 
accurate measurement of fibrous cap thickness with strong 
correlation to histology,45 and good sensitivity and specificity 
to distinguish plaque type.46 However, correct differentiation 
between calcium and lipid pool can be challenging with OCT, 
and its limited tissue penetration (1–3 mm) makes assessment 
of the entire plaque volume impossible. Image acquisition 
also requires a blood-free field, achieved through the injection 
of saline or contrast flushing during pullback. Other potential 
applications of OCT include elastography, OCT Doppler, and 
polarization-sensitive OCT.47
Because of its superior resolution, certain OCT appear-
ances might provide a glimpse into variations in plaque com-
position at the cellular level. In an ex vivo study using raw 
uncompressed data, OCT was used to quantify macrophages 
within the fibrous cap, seen as bright spots with higher signal 
intensity than surrounding structures and a sudden drop off 
in OCT signal.48 Although an intriguing finding, further work 
has revealed that only 23% of bright-spot positive regions on 
OCT specifically represent macrophages alone.49 Another ex 
vivo study in human coronaries using micro-OCT (spatial res-
olution of 1 μm) has revealed striking images of cellular and 
subcellular structures, including leukocytes tethered to endo-
thelial surface in similar appearance to electron microscopy.50 
For identification of TCFA, VH-IVUS and OCT have similar 
diagnostic accuracies (76–79%), which might in future be im-
proved by introduction of hybrid imaging catheters.51
NIRS uses diffuse reflectance near-infrared light (0.8–2.5 
μm wavelength) to create a chemogram of vessel wall com-
ponents, based on detection of varied absorption and scat-
tering patterns.52 Although NIRS can identify lipid content 
underlying high-risk plaque in human arteries through blood, 
as shown by ex vivo work,53 and clinical imaging,54 its major 
limitation is that it does not provide any structural informa-
tion on the plaque. This limitation can, in part, be overcome 
by NIRS–IVUS hybrid imaging, although this hybrid catheter 
still cannot robustly assess cap thickness.55
CT-Derived Plaque Morphology
In addition to defining coronary anatomy and luminal stenosis 
severity, CCTA can provide information on plaque morphol-
ogy and composition. Cap thickness and necrotic core are 
among the most important histological predictors of plaque 
rupture.38 Although the spatial resolution of CCTA is insuf-
ficient to allow measurement of cap thickness, necrotic cores 
of TCFAs are typically large enough for detection by CT.56 
Plaques can be readily classified as calcified, partially calci-
fied (<50%), or noncalcified plaques using CCTA. When as-
sessing plaque volume, CCTA tends to underestimate the size 
of noncalcified plaques and overestimate calcified plaque be-
cause of blooming artifact.57 The sensitivity of CCTA to detect 
noncalcific plaques with >1 mm intimal thickness on IVUS is 
roughly 90%.58
When compared with VH-IVUS, fibrous plaques display 
high attenuation on CT, whereas low attenuation occurs in 
relation to necrotic core and fibrofatty tissue.59 Good corre-
lations have also been shown between high-risk CT features 
and TCFA on OCT,60 and CT-derived plaque burden to cho-
lesterol deposition on NIRS.61 On the basis of IVUS stud-
ies, Hounsfield unit <30 on CCTA has been proposed as a 
cutoff for identification of lipid rich plaque, with 30 to 150 
Hounsfield unit for fibrous and >220 Hounsfield unit calcific.62 
However, using absolute CT attenuation values to determine 
plaque composition is challenging because of the influence of 
various factors, including size of necrotic core, wall thickness, 
measurement point, density of intraluminal contrast, slice 
thickness, and reconstruction filter.63,64 Contrast-adjusted at-
tenuation ranges can potentially improve accuracy of CCTA 
plaque component analysis.65
Unstable lesions imaged with CCTA in patients with acute 
coronary syndrome (ACS) tend be noncalcified, with low at-
tenuation and spotty calcification, larger plaque volume, and 
higher remodeling index compared with stable lesions in pa-
tients with chronic stable angina.62,66 Positive (outward) re-
modeling occurs because of compensatory enlargement of the 
vessel wall, leading to high-volume plaque with often little 
luminal narrowing; a feature associated with large lipid core 
and high macrophage count.67 The threshold for positive re-
modeling on CT is cross-sectional area >10% of the adjacent 
reference segment, and spotty calcification is defined as <3 
mm in all directions.62 Spotty calcification reflects small cal-
cific deposits within the plaque architecture, rather than true 
microcalcification, which occurs in response to inflammation 
and acts to destabilize the plaque by influencing local stress 
concentration.68 When detected by IVUS, spotty calcifica-
tion is associated with diffuse atherosclerosis and accelerated 
disease progression.69 The CT napkin-ring sign demonstrates 
an area of low attenuation adjacent to the vessel lumen, with 
surrounding higher-attenuation ring (Figure 2). This sign is 
suggestive of lipid-rich necrotic core and fibrous components 
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of TCFA.70 Low attenuation plaque, positive remodeling, and 
napkin-ring sign on CT are prognostic indicators linked to 
increased risk of MI.71,72 Interestingly, these high-risk plaque 
features are also 3 to 5 times more likely to occur in relation to 
FFR-positive lesions than in nonobstructive disease.73
MR-Derived Plaque Morphology
Coronary plaque analysis with MRI is much less useful than 
CCTA for clinical purposes; however, wall thickness can 
be measured with this method in proximal vessels.75 Using 
black-blood MRI, positive remodeling and increased coro-
nary wall thickness has been shown in asymptomatic patients 
with cardiovascular risk factors.76 Visualization of wall ede-
ma relating to culprit ACS lesions using T2-weighted short 
inversion recovery sequence MRI has also been reported.77 
Furthermore, hyperintense coronary signal on T1-weighed 
MRI might serve as a marker of high-risk plaque, which has 
been linked to clinical angina severity and increased cardio-
vascular risk (Figure 3).78,79 Hyperintense T1 plaque signal 
is most likely because of methemoglobin formation during 
subclinical plaque rupture or plaque hemorrhage; this is the 
most promising current MR technique for identifying high-
risk coronary plaques.
Unlike coronary imaging, carotid arteries are relatively 
stationary and of sufficient caliber to allow interrogation of 
plaque morphology using multicontrast weighted MRI or 
gadolinium-based intravenous contrast. T1 and T2 sequenc-
es on multicontrast weighted MRI distinguish plaque com-
ponents, which exhibit differing relaxation properties and 
signal intensity. Using this technique, carotid wall thickness 
can be accurately measured without intravenous contrast 
on a standard 1.5-T scanner, although better image quality 
due to improved signal- and contrast-to-noise ratios is seen 
with higher-field strength 3.0-T MRI.80 Fibrous tissue dis-
plays low signal on T1 and high-signal on T2-weighted MRI, 
whereas calcium is hypodense on both. With high-resolution 
3D time-of-flight MRI, fibrous cap appears as a juxtalumi-
nal band of low signal, which is absent in the presence of a 
thin or ruptured cap (Figure 2). Cap rupture detected by MRI 
has been shown in relation to recently symptomatic carotid 
plaques.74 Intraplaque hemorrhage causing high-intensity 
T1-signal in carotids arteries81 has been correlated to in-
creased C-reactive protein,82 symptomatic cap rupture,83 and 
increased risk of future stroke.84
MRI with gadolinium-based contrast can be used to quan-
tify the dimensions of fibrous cap and lipid-rich necrotic 
core.85 Lipid core displays lower enhancement than surround-
ing fibrous tissue on T1-weighted images post intravenous 
contrast. In addition to thin, or ruptured, cap and intraplaque 
hemorrhage, increased lipid core on MRI is an important 
prognostic marker.86 Dynamic contrast enhancement has also 
been applied to MR carotid imaging. With this method, dy-
namic images acquired pre- and post-gadolinium contrast in-
jection are analyzed using kinetic modeling to derive transfer 
constant (Ktrans), which is linked to carotid plaque macrophage 
content and neovascularization.87
Figure 2. Noninvasive imaging of atherosclerotic plaque 
composition. Coronary artery shown in cross section, 
demonstrating napkin-ring sign on contrast-enhanced 
computed tomography (CT) (A) with corresponding histology 
confirming presence of advanced fibroatheroma (B). Area of 
low attenuation (white star) abutting lumen (L) seen on CT 
corresponds to necrotic core (black stars) on histology. High-
attenuation circumferential outer rim on CT image (dashed 
red line) corresponds to fibrous plaque tissue (black arrows). 
Magnetic resonance image (MRI) of carotid artery shown in axial 
view with 3D time-of-flight MRI (C). Thin fibrous cap (blue arrows) 
demonstrated by missing area of hypodense juxtaluminal band 
(red asterisk) on MRI, confirmed by histology (D). Adapted from 
Maurovich-Horvat et al70 (A and B; copyright ©2010, Elsevier) 
and Yuan et al74 (C and D; copyright ©2002, American Heart 
Association, Inc) with permission of the publishers.
Figure 3. Hyperintense coronary signal on T1-weighted 
magnetic resonance image (MRI). A, T1-weighted MRI showing 
hyperintense signal within the wall of the right coronary artery 
(arrow), highlighted by fused MRI (circle, B); C, X-ray angiography 
shows severe stenosis in corresponding coronary segment, 
with lipid-rich plaque in this same region on optical coherence 
tomography (OCT) (D). Adapted from Matsumoto et al78 with 
permission of the publisher. Copyright ©2015, Elsevier.
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Molecular Imaging
Mechanisms underlying the pathobiology of atherosclerosis 
and its clinical consequences can be illuminated using highly 
sensitive molecular imaging probes. Noninvasive nuclear and 
MR-based molecular imaging platforms have been most ex-
tensively studied in vivo, although molecular CT, ultrasound, 
and near-infrared fluorescence (NIRF) are among other 
emerging research methods. The advantage of PET over other 
techniques, including SPECT and MRI, is its superior sen-
sitivity to detect molecular signals, even at picomolar tissue 
concentrations. However, limited spatial resolution (4–5 mm) 
means that images must be coregistered with CT or MRI for 
precise anatomic localization of the PET signal. Among other 
applications, molecular probes used in atherosclerosis imag-
ing can be used to quantify vascular inflammation, early calci-
fication, plaque hypoxia, and neoangiogenesis.
Molecular Methods for Imaging Inflammation
Within the arterial wall, innate and adaptive immune respons-
es triggered largely by clinical cardiovascular risk factors are 
major determinants of atherosclerotic progression and plaque 
rupture. Macrophages direct proinflammatory cell signaling 
cascades underlying high-risk plaque morphology, thus, pre-
senting an attractive molecular imaging target to track vascu-
lar inflammation.
Nuclear Inflammation Imaging: PET and SPECT
18F-fluorodeoxyglucose (FDG) is a radio-labeled glucose 
analogue used commonly in PET imaging for a variety of di-
agnostic purposes. Its half-life is 110 minutes and maximum 
positron range 2.4 mm. After intravenous injection, decay re-
sults in the emission of positrons and occurs at a predictable 
rate. 18F-FDG is taken up by cells that metabolize glucose, 
where it becomes metabolically trapped after phosphorylation 
into 18F-FDG-6-phosphate, as it lacks the necessary 2′ hydrox-
yl group to continue glycolysis. The PET scanner detects an-
nihilation (γ) photons, which result when an emitted positron 
encounters an electron. Tomographic images displaying the 
distribution of injected radio-labeled tracer within the body 
are reconstructed in 3D, with corrections applied for attenua-
tion, dead time, scatter, and random coincidences. Intracellular 
accumulation of 18F-FDG can be used as a biomarker of meta-
bolic activity. In atherosclerosis, vascular 18F-FDG uptake at 
late time points reflects increased activity of macrophages and 
to a lesser extent other immune cell types. For the purpose of 
vascular imaging, the optimal dose is 185 to 300 MBq and 
circulation times of over 2 hours are recommended.88
18F-FDG PET is an important research tool for studying 
vascular inflammation (Figure 4), which has been validated 
by both clinical and preclinical studies across several vascu-
lar territories. The 18F-FDG signal shows strong correlation to 
macrophage density (%CD68 staining) within excised carotid 
plaques, presence of cardiovascular risk factors, Framingham 
risk score, and inflammatory biomarkers.89 Carotid artery 
18F-FDG uptake also relates to high-risk plaque morphology,90 
and carotid and aortic signals can help predict future cardio-
vascular risk.91–93 In atherosclerosis, 18F-FDG uptake seems 
to be highest during early foam cell formation94 and does 
not typically colocalize with areas of macroscopic vascular 
calcification.95 Interestingly, 18F-FDG signals are higher in low 
shear-stress induced macrophage-rich carotid plaques com-
pared with stable plaques in mice,96 and possibly also among 
proinflammatory M1 macrophage subtypes.97 Although mea-
surement of vascular 18F-FDG signals using established tech-
niques is highly reproducible with low short-term interscan 
variability, accuracy of this method could be further improved 
by adoption of standardized imaging protocols.98
However, as 18F-FDG is taken up by all cells with ac-
tive glucose metabolism, it provides a nonspecific marker 
of inflammation in atherosclerosis. Vascular 18F-FDG uptake 
is also influenced by plaque hypoxia99 and the efficiency of 
tracer delivery by the microcirculation.100 Moreover, high 
myocardial muscle cell uptake often prevents interpretation 
of coronary signals, even with strict dietary manipulation.101 
As a result of these limitations, other PET tracers have been 
evaluated for use in atherosclerosis imaging. Several of these 
tracers might be specific for macrophage activity, and bet-
ter suited for coronary imaging than 18F-FDG because of 
low myocardial uptake, including 11C-PK11195 and other 
TSPO (translocator protein) receptor ligands, 18C-choline, 
and somatostatin receptor binding tracers, such as 68Ga-
DOTATATE ([1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-
tetraacetic acid]-D-Phe(1),Tyr(3)-octreotate).89 Macrophage 
and hematopoietic cell proliferation have also been imaged 
using 18F-fluorothymidine PET in preclinical atherosclerosis 
models and humans; in this study, higher carotid and aortic 
18F-fluorothymidine uptake was observed in patients with 
Figure 4. Positron emission tomography (PET) inflammation 
imaging. Computed tomographic (CT) angiography of 
symptomatic left internal carotid stenosis (arrows); sagittal (A) 
and axial (C) views. B, D, Fused 18F-fluorodeoxyglucose (FDG) 
PET–CT demonstrates high uptake relating to the symptomatic 
carotid plaque. E, Coronary CT angiogram of left circumflex 
coronary artery lesion (red arrow) with spotty calcification (white 
arrows); F, fused 68Ga-DOTATATE PET–CT demonstrates high 
signal in relation to the inflamed coronary plaque.
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CVD risk factors compared with controls, as well as a weak 
positive correlation between 18F-fluorothymidine and 18F-FDG 
aortic uptake.102
Several SPECT tracers have also been evaluated for in-
flammation imaging. Radio-isotopes used to make SPECT 
tracers typically have longer half-lives and are more widely 
accessible than those used for PET. Although SPECT has a 
lower spatial resolution (10–16 mm) compared with PET, 
image quality can potentially be improved by use of new 
scanners equipped with cadmium–zinc–telluride solid-
state detectors.103 Among the list of experimental targets for 
SPECT inflammation imaging are IL-2 receptors on acti-
vated T lymphocytes,104 folate receptor-β expressed by M2 
macrophages,105 endothelial vascular cell adhesion molecule 
(VCAM-1) expression,106 and exposed phosphatidylserine on 
cell surface of apoptotic macrophages.107
Nanoparticle Imaging: MRI, CT, and Ultrasound
Nanoparticles used in molecular atherosclerosis imaging 
are typically 10 to 100 nm in size. Paramagnetic iron oxide 
particles, such as ultrasmall supraparamagnetic iron oxide 
(USPIO), generate MRI signal drop when internalized by 
macrophages owing to changes in the local magnetic field 
causing T2-shortening.21,108 USPIO signal drop has been de-
tected in patients with symptomatic carotid plaques109 and 
correlates to macrophage-rich plaque areas.110 Experimental 
conjugated iron oxide particles have been developed to target 
P-selectin and VCAM-1 adhesion molecules,111 and scavenger 
receptors on foam cells.112 Plaque imaging using an elastin-
based MRI contrast agent has also been performed in preclini-
cal studies.113
N1177 is a suspension of crystalline iodinated nanopar-
ticles with high affinity for macrophages, which has been 
imaged using CT in a rabbit model.114 A gold high-density 
lipoprotein nanoparticle has also been tested in a preclinical 
atherosclerosis model, using spectral multicolor CT to iden-
tify the gold contrast agent based on its energy-dependant 
photon attenuation.115 Contrast-enhanced ultrasound using 
targeted microbubbles is another molecular imaging tech-
nique. Potential advantages of ultrasound over other methods 
include portability, low equipment cost, and speed of acquisi-
tion. Microbubbles contain compressed gas, which undergo 
volumetric oscillation and expansion in an acoustic field.116 
Signal from targeted microbubbles retained in tissue can be 
destroyed with low-frequency, high amplitude ultrasound 
energy creating a null signal after image acquisition allow-
ing administration of subsequent target agents. In preclinical 
studies, microbubbles conjugated to activated neutrophils, α5-
integrins, VCAM-1,117 and P-selectin have been tested.118
Near-Infrared Fluorescence
Intravascular NIRF is an emerging molecular imaging method 
that lacks ionizing radiation. In a feasibility study, a 2D rota-
tional 2.9-F automated pullback intravascular NIRF catheter 
with protease-activated fluorescence agent was successfully 
used to obtain 360° high-resolution real-time images of arte-
rial inflammation in a rabbit atherosclerosis model and after 
stent implantation.119 A fully integrated high-speed NIRF-
OCT imaging catheter has also been tested, using indocyanine 
green to detect inflamed lipid-rich atheroma.120 Indocyanine 
green is currently used for clinical NIRF ophthalmologic im-
aging. Translation of NIRF technology to clinical atheroscle-
rosis imaging trials is expected within the next 1 to 2 years.121
PET Imaging of Microcalcification, Hypoxia, and 
Neoangiogenesis
Aside from inflammation, several other molecular processes 
that contribute to the pathogenesis of atherosclerosis can be 
imaged using PET. Early vascular calcification occurring in 
response to intense plaque inflammation, and below the reso-
lution of CT, can be detected using 18F-sodium fluoride (NaF) 
in advanced high-risk stable and culprit coronary lesions,5 and 
possibly also in earlier stages during neointimal thickening.122 
In symptomatic carotid arteries, 18F-NaF binding takes place 
in areas of pathological mineralization and is related to surface 
area of exposed hydroxyapatite.123 Hypoxia develops deep 
within advanced atheroma, where it acts as a stimulus for new 
microvessel formation and promotes low-density lipoprotein 
accumulation and inflammation.124 Using 18F-HX4 (flortani-
dazole), plaque hypoxia has been shown in relation to carotid 
wall thickness and 18F-FDG uptake.125 18F-fluoromisonidazole 
has also been applied to study atherosclerosis and correlated 
to histologically determined hypoxic plaque areas in preclini-
cal and clinical studies.126,127 By targeting integrin ανβ3 ex-
pression in angiogenic endothelial cells, neoangiogenesis can 
also potentially be imaged using R-G-D-based tracers with 
PET128 and SPECT.129
Biomechanical Analysis
The nonuniform distribution of atherosclerotic lesions within 
the vascular system suggests local stimuli contribute to plaque 
initiation and growth. Specific points within the arterial sys-
tem seem to be preferentially affected, including bifurcations 
and the inner curvature of vessels, regions where wall shear 
stress is typically reduced. Shear stresses result from blood 
flow creating frictional (axial) forces on the endothelial sur-
face and changes in shear stress induced by arterial geometry 
are known to result in endothelial injury, inflammation, and 
altered gene expression influencing vasoreactivity and ves-
sel remodeling.130 Persistently low shear-stress seems to be 
the most important biomechanical factor for TCFA forma-
tion.131 Structural stress because of tensile (circumferential) 
forces may also regulate plaque behavior, dictating its ability 
to withstand mechanical load.132 The influence of structural 
stress in plaques is most important in the presence of a weak-
ened cap, where high mechanical stress is most likely to pro-
mote plaque rupture. Computational modeling of shear and 
structural stresses is possible using data from noninvasive and 
invasive imaging.
Wall shear stress is typically estimated using computation-
al fluid dynamics simulations that mimic coronary blood-flow 
based on reconstructed 3D geometry of the vessel. Anatomic 
information used for computational fluid dynamics simulation 
can be obtained with CCTA (Figure 5), or intravascular imag-
ing combined with biplane angiography.133 Plaque structural 
stress is dependent on a variety of factors including arterial 
pressure, plaque composition and structure, tissue material 
properties, and luminal geometry. Plaque structural stress can 
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be estimated using imaging data from VH-IVUS,134 and other 
methods, by using engineering techniques such as finite ele-
ment analysis. Virtual computed FFR (CTFFR) can also be de-
termined using biomechanical modeling, which shows good 
correlation to invasive FFR (r=0.7; P<0.001),135 with strong 
predictive power (area under the curve, 0.9) to detect CAD 
stenosis >50% when evaluated in clinical studies.136 CTFFR 
can also potentially be used simulate hemodynamic changes 
resulting from stenting when planning invasive procedures137 
and was shown to be useful as a method to streamline referrals 
for invasive angiography in a prospective longitudinal trial.138
Risk Prediction and Biological Insights: What Have 
We Learned from Atherosclerosis Imaging Studies?
Fundamentally, the aim of atherosclerosis imaging is to iden-
tify patients most at risk of future clinical events, in an ef-
fort to best direct care and improve long-term outcomes. 
Imaging-based biomarkers for CVD provide important prog-
nostic information, to compliment traditional clinical risk-
stratification methods. These measurable imaging parameters 
are selected on their ability to identify (a) subclinical CVD 
in asymptomatic patients with risk factors, (b) obstructive or 
high-risk lesions in those with symptomatic CVD, or (c) high-
risk patients with active CVD and extensive disease burden. 
Although tremendous resources over preceding decades have 
been devoted toward vulnerable plaque imaging, current evi-
dence from prospective imaging studies fails to support this 
tactic, calling for a wider approach.139 Nevertheless, imaging 
atherosclerosis provides unparalleled insight into mechanisms 
underlying disease severity and progression, which continue 
to shape patient management. Here, we discuss the predic-
tive value offered by each clinical imaging strategy, what has 
been learned about the natural history of atherosclerosis from 
important clinical studies, and the future role of multimodal 
imaging.
Methods for CVD Screening
Limitations of clinical-risk scores drive search for cost-effec-
tive, noninvasive imaging tests, which can be rolled-out for 
screening individuals at risk of CVD. CAC scanning offers 
a simple, rapid, and reliable method of quantifying coronary 
calcium, which is pathognomic of established atherosclero-
sis. It is a powerful screening tool for asymptomatic patients 
with low to intermediate CVD risk, including those with 
diabetes mellitus, and can potentially improve adherence to 
lifestyle advice and medication.11 In the Multi-Ethnic Study 
of Atherosclerosis (MESA), which included 6722 patients 
followed up for median 3.8 years, increasing CAC con-
ferred incremental rise in hazard ratio with a nearly 10-fold 
increased risk of a coronary event in those with CAC >300, 
and no difference among racial or ethnic groups.140 However, 
as dense calcium deposits seem to offer plaque stability,141 
and progress with age and statin use,142,143 a high CAC score 
is perhaps most helpful as marker of disease burden, rather 
than for predicting likelihood of an event originating from 
an individual plaque. Importantly, for individuals with low 
and intermediate CVD risk, a CAC of zero is associated with 
<1% annual mortality over a 15-year period, irrespective 
of age or sex.144 As a result, absence of CAC reclassifies up 
to 50% of patients eligible for statins based on clinical risk 
scores alone.145 Carotid ultrasound is another important CVD 
screening tool; in the BioImage study (A Clinical Study of 
Burden of Atherosclerotic Disease in an At-Risk Population) 
of 5808 asymptomatic U.S. adults, 3-D assessment of carotid 
Figure 5. Shear stress simulation and plaque progression. 3D coronary reconstruction at baseline (A) and 3-year follow-up (C); outer 
vessel-wall shown in a semitransparent fashion to allow visualization of plaque distribution. B, E, Shear stress simulation performed at 
baseline; low stress shown in blue and high in red. Plaque burden at baseline (D) and follow-up (F); green indicates minimal thickness 
and red increased plaque thickness. There is significant plaque progression in the region of low shear stress at baseline (circle). Image 
courtesy of Dr Christos Bourantas.
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plaque burden using this inexpensive and portable technique 
appeared to provide similar risk prediction to coronary CAC 
scanning.146
Imaging Biomarkers to Predict CVD Risk
The natural history of atherosclerosis is that of a slowly pro-
gressive, chronic disease; however, cardiovascular events 
arise suddenly and unexpectedly, with often devastating con-
sequences for patients. In clinical practice, CAD is usually 
diagnosed on the basis of symptoms, plus the aid of anatomic 
or functional tests. Despite availability of numerous diagnos-
tic tests, the timing and location of acute plaque disruption 
instigating clinical events cannot be reliably predicted by 
pre-existent anatomic stenosis severity, or indeed any other 
currently available method. This is because chronically ob-
structive plaques are less rupture-prone than TCFA owing 
to thick, heavily calcified fibrous caps,39 and only a minority 
of ruptured plaques result in clinical symptoms. More often, 
subclinical plaque rupture and healing occurs in the absence 
of multiple contributory factors promoting acute vessel occlu-
sion.147 This highlights the need to consider additional factors 
beyond stenosis severity, including ischemic burden, plaque 
volume and vulnerability, microvascular and endothelial dys-
function, predilection to vasospasm, platelet function and co-
agulation, and current metabolic demands and inflammatory 
state.148
Stenosis Severity and Myocardial Ischemia
Current guidelines on coronary revascularization for symp-
tomatic benefit in patients with stable CAD advocate a man-
agement strategy that incorporates functional assessment of 
myocardial ischemia in addition to angiography. Detection 
of ischemia helps to confirm obstructive lesions underlying 
angina symptoms, and is, itself, a strong prognostic marker. 
Indeed, long-term follow-up of the Fractional Flow Reserve 
Versus Angiography for Multivessel Evaluation (FAME) 
and Deferral versus Performance of Percutaneous Coronary 
Intervention of Functionally Nonsignificant Coronary 
Stenosis (DEFER) studies demonstrate the role of functional 
assessments to guide PCI for reducing stent use and need for 
repeat procedures.27,149 However, FFR-guided PCI does not 
seem to significantly lower rates of death or MI. Lack of im-
provement in hard-outcomes, such as MI or death, after PCI 
for stable angina versus medical therapy alone echoes previ-
ous findings of Clinical Outcomes Utilizing Revascularization 
and Aggressive Drug Evaluation (COURAGE),150 Bypass 
Angioplasty Revascularization Investigation 2 Diabetes 
(BARI-2D),151 and Medical, Angioplasty or Surgery Study II 
(MASS II) studies.152 This highlights potential inadequacies 
of a purely lesion-targeted approach and suggests an indirect 
relationship between individual stenosis severity and long-
term prognosis.
It is clear that patients with multiple coronary stenosis are 
most at risk of future cardiac events, and that survival benefit 
is offered by coronary artery bypass surgery versus medical 
therapy±PCI in appropriately selected patients with multives-
sel CAD, particularly diabetics.153 For patients with left main 
stem, or 3 vessel CAD, angiographic anatomic complexity 
graded according to the SYNergy between PCI with TAXUS 
and Cardiac Surgery (SYNTAX) score is an important deter-
minant of clinical outcomes when contemplating PCI versus 
coronary artery bypass surgery.154 The benefit of coronary 
artery bypass surgery over PCI for long-term survival might 
be because of the fact that a by-pass graft, as long as its pat-
ent, provides some protection against atherothrombotic events 
arising from any site proximal to the anastomosis, not just the 
original obstructive lesion.
When moving away from a plaque-centric model, stenosis 
severity remains nonetheless important as a marker of disease 
burden, and a degree of pre-existent luminal narrowing also 
seems necessary for acute thrombo-occlusion after plaque 
rupture.155 Major adverse clinical event prediction using FFR 
might also be improved among the most severe FFR values,156 
and when combined with additional measures of microcircula-
tory hemodynamics.31 However, the link between myocardial 
ischemia and long-term prognosis remains elusive. Although, 
in theory, changes in local flow and stress because of hemo-
dynamic obstruction could increase risk, the overall low MI 
rate in patients with stable angina,3 and apparent lack of sur-
vival benefit from ischemia-directed PCI suggest that myo-
cardial ischemia might instead serve as a marker of advanced 
disease. The ongoing International Study of Comparative 
Health Effectiveness with Medical and Invasive Approaches 
(ISCHEMIA; NCT01471522) study aims to tackle this im-
portant question.
Plaque Burden and Vulnerability
Despite our ability to identify and characterize high-risk 
plaques, insights from prospective intravascular imaging tri-
als question the significance of such findings. In Providing 
Regional Observations to Study Predictors of Events in the 
Coronary Tree (PROSPECT),157 VH-IVUS in Vulnerable 
Atherosclerosis (VIVA),158 and European Collaborative 
Project on Inflammation and Vascular Wall Remodeling in 
Atherosclerosis (ATHEROREMO-IVUS),159 the vast major-
ity of TCFA identified with VH-IVUS did not result in sub-
sequent MI or death over a period of 3 to 4 years. Although 
this important finding can, in part, be explained by the overall 
low positive predictive value of VH-IVUS to detect TCFA,51 
there are several other potential contributory factors. First, we 
now know that there is a high incidence of subclinical plaque 
rupture at nonculprit coronary sites in patients with both ACS 
and stable CAD.160 We also know that transition to and from 
thin and thick-cap atheroma is relatively common within a 
12-month period,161 and that cycles of rupture and healing 
can lead to variable rates of plaque progression.162 Indeed, for 
many patients with ACS rapid plaque progression occurs over 
a period of weeks to months,163 culminating in high burden of 
vulnerable disease and significant intraluminal stenosis acting 
as a nidus for thrombo-occlusive events.164
Although most VH-IVUS defined TCFA do not become 
culprit lesions, high-risk plaque identification is nonethe-
less valuable as their presence portends future consequenc-
es of pancoronary vulnerability and disease progression.165 
Furthermore, risk prediction can be improved by adopting an 
integrative approach that combines multiple markers of disease 
severity. In the Prediction of Progression of Coronary Artery 
Disease and Clinical Outcomes Using Vascular Profiling of 
 at UNIV OF EDINBURGH on April 26, 2016http://circres.ahajournals.org/Downloaded from 
760  Circulation Research  February 19, 2016
Endothelial Shear Stress and Arterial Plaque Characteristics 
(PREDICTION) study, the combination of large plaque bur-
den and low endothelial shear stress at baseline provided sig-
nificant predictive value for identification of a lesion treated 
with PCI within 1 year.166 CCTA provides a good means to 
monitor plaque progression noninvasively. In a study of 3158 
patients followed up for a mean 3.9 years after CCTA, both 
CT-defined high risk-plaque (positive remodeling or low at-
tenuation) and plaque progression were important predictors 
of ACS, although the cumulative number of events was simi-
lar among patients with or without high-risk CT features at 
baseline (Figure 6).167 In the Prospective Multicenter Imaging 
Study for Evaluation of Chest Pain (PROMISE) study of 
roughly 10 000 symptomatic patients with intermediate pre-
test probability of CAD, a strategy of initial CCTA did not 
improve clinical outcomes when compared with functional 
testing over a median follow-up of 2 years.168 Use of semiau-
tomated CT plaque segmentation tools,56 segmental calcium 
scoring,169 and coronary disease burden scores might further 
improve predictive accuracy of CCTA.170
Disease Activity
Atherosclerosis is driven by local and systemic inflammation, 
best imaged in vivo using 18F-FDG PET. In the Dublin Carotid 
Atherosclerosis Stroke Study, carotid artery inflammation de-
tected by 18F-FDG was useful for identifying patients most 
at risk of early stroke recurrence, independent of age and 
stenosis severity.91 A retrospective study of 513 cancer-free 
patients also showed aortic 18F-FDG PET signal can predict 
CVD events independent of traditional risk factors (HR, 4.71; 
P<0.001), with nearly 30% net reclassification improvement 
over Framingham risk score in the highest-risk group and in-
verse relationship between PET signal intensity and timing of 
event.92 In a study of 1089 asymptomatic adults, both high 
carotid 18F-FDG uptake and carotid intima media thickness 
predicted stroke occurrence within 4 years; but only 18F-FDG 
provided additive value above Framingham risk score.93 After 
MI, increased 18F-FDG activity in the aorta also shows posi-
tive correlation to plasma troponin level.171 Unlike 18F-FDG, 
which has limited use in the coronaries, 18F-NaF localizes to 
individual coronary plaques with minimal background uptake 
and can reliably identify culprit coronary plaques post MI.5 
Ongoing studies aim to evaluate the efficacy of prospec-
tive 18F-NaF coronary microcalcification imaging to iden-
tify high-risk prospective culprit lesions (NCT02110303 and 
NCT02278211).
Taking a wider view, imaging systemic networks of in-
flammation can potentially help clinical risk stratification and 
translational research. Using SPECT with 99mTC labeling of 
autologous peripheral blood monocytes, increased in vivo 
leukocyte trafficking was shown in relation to carotid plaque 
inflammation detected by 18F-FDG PET and atherosclerotic 
burden on MRI.125 The importance of measuring systemic 
inflammation was also demonstrated by a study that showed 
increased splenic metabolic activity after ACS to be an inde-
pendent predictor of subsequent CVD events.172 Ectopic fat is 
increasingly recognized as another important CVD risk fac-
tor173; 18F-FDG uptake in tissue fat can be predicted by body 
weight and is strongly linked to arterial inflammation.174
Multimodal Imaging Strategies
Given the highly complex, multifactorial pathophysiology 
of atherosclerosis and its progression to symptomatic plaque 
rupture, accurate risk prediction can potentially be improved 
in the future by multimodal imaging strategies that incorpo-
rate information from several complimentary imaging tools. 
This combined approach will be particularly relevant when 
assessing individual plaque vulnerability in patients with 
stable angina who might benefit from PCI. For example, 
PCI could be helpful to stabilize a high-risk lesion identi-
fied on basis of CT or VH-IVUS, if there is also evidence 
of hemodynamic obstruction, inflammation, or altered shear 
stress. With this aim, hybrid intravascular imaging catheters 
are being developed to combine, for example, detailed ana-
tomic information gained from OCT imaging with simulta-
neous measurement of plaque composition using VH-IVUS 
or NIRS. Similarly, noninvasive hybrid PET/CT and PET/
MR systems can in theory provide integrated measurement 
of factors including stenosis severity, markers of hemody-
namic significance, myocardial viability, plaque burden and 
composition, and metabolic activity. Of course, not all infor-
mation will be required for every case.
Figure 6. Prediction of acute coronary syndrome (ACS) by high-risk computed tomographic (CT) features. Results of prospective 
imaging study involving 3158 patients, aimed to evaluate whether CT-derived plaque characteristics can predict midterm likelihood of 
ACS. Cumulative event rate for patients with high-risk CT features (high-risk plaque [HRP] (+); low attenuation or positive remodeled 
plaque) identified at baseline vs those without high-risk CT features (HRP (−); A). Although the event rate in HRP (+) patients is higher than 
HRP (−), the number of patients in the HRP (+) group was 10-fold lower resulting in a similar cumulative number of events among the 2 
groups (B). Adapted from Motoyama et al167 with permission of the publisher. Copyright ©2015, Elsevier.
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Imaging for Drug Discovery and End Point for 
Clinical Trials
Research to identify and evaluate new atherosclerosis treat-
ments is challenging. Despite best efforts only a handful of 
drugs have been proven to reduce atherosclerotic events. The 
ultimate step in drug evaluation (phase 3 trials) is to assess im-
pact on clinical end points. Because of the nature of the disease, 
phase 3 atherosclerosis drug trials require enrolment of large 
numbers of patients (at times >20 000) and long follow-up pe-
riods, with typical costs exceeding $350 million.175 As a result 
of these enormous costs, it is important to gain clear insights 
of a drug’s potential for clinical efficacy during phase 2 trials. 
Atherosclerosis imaging allows measurable assessments of 
disease progression and activity, revealing early signals about 
potential drug effects, which can inform decisions and allow 
selection of drugs for phase 3 evaluation that have the most 
chance for success. In theory, imaging could potentially be used 
to select high-risk patients in effort to reduce the sample size 
needed in clinical outcome studies by increasing the outcome 
event rate; however, the practicality of this approach has yet 
to be determined. In certain circumstances, imaging data could 
also be used to help identify potential subgroups of patients in 
large trials who might benefit most from a particular treatment.
Both noninvasive and intravascular imaging modalities 
have been used to monitor effects of statins and other anti-
atherosclerosis drugs. Noninvasive methods are preferable for 
serial imaging in drug trials because of potential risks associ-
ated with invasive procedures. High participant drop out rates 
are also seen when invasive methods are used.176 However, 
much greater detail on plaque volume and composition can 
be gained with intravascular imaging, and radiation exposure 
is another major consideration when choosing between dif-
ferent imaging modalities. Change in plaque volume, compo-
sition, and inflammation has been used as imaging outcome 
measures during drug evaluation; however, clinical outcomes 
remain the only recognized route to drug approval. Luminal 
stenosis severity is less useful as this does not change much 
even with the most effective medical therapies, owing to the 
effect of positive vessel remodeling. Here, we provide a brief 
overview of some of the most informative atherosclerosis drug 
trials with imaging end points.
Intravascular Imaging: IVUS and OCT
The beneficial actions of statins on CVD risk result from slow-
ing disease progression and plaque stabilization, among other 
pleiotropic effects.177 Reduction in plaque volume after treat-
ment with statins has been demonstrated by numerous clini-
cal studies using intravascular imaging with IVUS and OCT, 
including A Study to Evaluate the Effect of Rosuvastatin on 
Intravascular Ultrasound-Derived Coronary Atheroma Burden 
(ASTEROID),178 Reversal of Atherosclerosis with Aggressive 
Lipid Lowering (REVERSAL),179 Early Statin Treatment in 
Patients With Acute Coronary Syndrome (ESTABLISH),180 
and Integrated Biomarkers and Imaging Study-4 (IBIS-4).181 
In 1 study, the combination of high-dose atorvastatin plus 
ezetimibe showed greater regression in plaque volume deter-
mined by IVUS than statins alone, mirroring changes in serum 
lipid levels.182 Significant reduction in plaque volume has also 
been shown following treatment with the angiotensin II recep-
tor blocking agent olmesartan, when monitored with IVUS 
in 247 patients with stable angina over 14-month period.183 
Studies using OCT to measure cap thickness have demonstrat-
ed a plaque stabilizing effect of statins, leading to increased 
cap thickness.184 Paradoxically, progression of plaque calcifi-
cation is another potentially protective effect of statins shown 
by IVUS (Figure 7)143,181; however, change in coronary calci-
fication has yet to undergo clinical evaluation as a marker of 
altered risk.185
Noninvasive Imaging: Ultrasound, MRI, and CT
In patients with subclinical atherosclerosis, statins result in 
significant reduction in carotid intima media thickness when 
measured with ultrasound and MRI.186,187 Using 1.5-T carotid 
MRI, significant reduction in lipid-rich necrotic core content, 
but not plaque volume, was observed after treatment with ro-
suvastatin for 2 years in a randomized, double-blind phase 3 
trial,188 and another in study after 1-year.189 Dalcetrapib, a cho-
lesterol ester transfer protein (CETP) inhibitor that increases 
high-density lipoprotein, failed to reduce carotid artery wall 
thickness or volume measured by MRI190; a finding that pre-
saged the dal-OUTCOMES trial, which showed that this 
drug also did not improve clinical outcomes.191 The National 
Institute on Aging (NIA) plaque study showed that the 
Figure 7. Effects of statins on plaque morphology evaluated by intravascular imaging. Summary of a post hoc analysis of 8 
prospective randomized trials using serial intravascular ultrasound to detect change in percent atheroma volume (PAV; A), total atheroma 
volume (TAV; B), and calcium index (Cal) in response to low-intensity statin treatment (LIST) and high-intensity statin treatment (HIST). 
Significant plaque regression, with increased coronary atheroma calcification is observed in both low- and high-dose statin groups. 
Adapted from Puri et al143 with permission of the publisher. Copyright ©2015, Elsevier.
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addition of niacin on top of statin therapy also did not reduce 
carotid wall volume,192 supporting clinical outcome data from 
the Atherothrombosis Intervention in Metabolic Syndrome 
with Low HDL/High Triglycerides: Impact on Global Health 
Outcomes (AIM-HIGH) study.193 In the Atorvastatin Therapy: 
Effects on Reduction of Macrophage Activity (ATHEROMA) 
study, reduction in carotid plaque inflammation in response to 
high-dose statin treatment was observed using USPIO MRI 
after just 3 months.194 Effects of the anti-inflammatory IL-1β 
monoclonal antibody canakinumab on carotid plaque burden 
will be quantified using MRI in a prespecified substudy of 
Cardiovascular Risk Reduction Study, Reduction in Recurrent 
Major CV Disease Events (CANTOS; NCT01327846). 
Although CCTA can potentially provide a useful noninvasive 
means of monitoring effects of drugs on coronary plaque vol-
ume and composition in noncalcified lesions,195 further evalu-
ation of this application is needed, particularly in view of the 
added radiation risk.
18F-Fluorodeoxyglucose Positron Emission 
Tomography
Vascular inflammation imaging with 18F-FDG PET has been 
applied in several drug trials evaluating statins, and several 
other drugs, where anti-inflammatory effects (or lack there-
of) were predictive of clinical efficacy. Significant reduc-
tion in plaque inflammation after treatment with statins has 
been demonstrated using 18F-FDG PET,196 with significant 
incremental dose–response197; consistent with known effects 
on low-density lipoprotein lowering and clinical outcomes. 
Reduction in arterial inflammation after treatment with pio-
glitazone, a diabetic drug with proven secondary preventive 
value, has also been observed.198 Conversely, failure to reduce 
arterial inflammation might suggest lack of clinical efficacy in 
atherosclerosis. Dalcetrapib, which is now known to be clini-
cally ineffective, did not reduce arterial inflammation by any 
of the prespecified PET imaging measures in the dal-PLAQUE 
study.190 Similarly, a lipoprotein-associated phospholipase A2 
inhibitor did not decrease atherosclerotic inflammation on 
PET imaging199 and failed to improve clinical outcomes in 2 
randomized-controlled clinical trials.200,201
Challenges of Noninvasive Coronary Imaging
Atherosclerosis imaging, particularly noninvasive methods, 
when focused on small and constantly moving coronary ar-
teries, presents several hurdles. Technological advancements 
leading to reduction in radiation exposure and improved im-
age quality, better spatial resolution, and more accurate mo-
tion correction are essential for the field to progress.
Radiation Exposure
Most cardiovascular imaging techniques, including CT, 
SPECT, PET, and x-ray angiography, rely on radiation ex-
posure to generate images of the heart and blood vessels. 
Significant radiation exposure is associated with an increased 
risk of cancer. Although the risk from a single scan is low, 
the effect of radiation exposure is cumulative over a life-time. 
Consequently, this restricts available methods for serial imag-
ing and population screening; particularly as many patients 
will require additional scans for noncardiac reasons. Efforts to 
reduce exposure to ionizing radiation from medical imaging 
represent a major scientific endeavor. In particular, the ad-
vent of prospective cardiac gating and advances in CT scan-
ner technology have dramatically reduced radiation exposure 
during CCTA. The average effective dose from CCTA with 
retrospective gating is 12 mSv; however, this is routinely re-
duced to ≈3.5 mSv with prospectively trigging. Diagnostic 
image quality is even possible at <1 mSv (comparable to chest 
x-ray exposure) using low tube-voltage (80–100 kV) and cur-
rent (150–210 mA), along with iterative data reconstruction.202 
Although MRI has a clear advantage, being radiation free, 
reliable imaging of the entire coronary vasculature remains 
elusive and hybrid PET/MR systems are not widely available.
Spatial Resolution and Partial Volume Effects
The small caliber of coronary arteries, even in proximal seg-
ments (2–5 mm), demands high resolution anatomic images 
to differentiate specific plaque characteristics on CT and pre-
cisely localize PET signals. As a result, limited spatial reso-
lution and partial volume effect can lead to problems such 
as calcium blooming artifact, resulting in overestimation of 
stenosis severity. Dual-energy CT is one plausible method to 
increase tissue contrast and allow better coronary plaque char-
acterization115; however, this improvement seems to occur at 
the expense of reduced image quality compared with single 
energy scans in the clinical setting.203 Although coronary PET 
imaging is also problematic because of spill-in and spill-out 
of tracer activity, which can affect accurate signal quantifi-
cation, this limitation can be partly corrected using a range 
of methods.204 Moreover, simultaneous motion correction and 
resolution recovery using PET/MR, coupled with advances in 
detector technology and signal processing methods, are likely 
to improve spatial resolution of PET.205
Motion Artefacts
The coronary arteries move with each heartbeat and respi-
ratory cycle, creating complex motion patterns. X-ray angi-
ography has high temporal resolution, allowing tracking of 
coronary movement in real time. Unlike invasive imaging, 
motion correction is a fundamental requirement for any non-
invasive coronary imaging modality. Modern CT scanners are 
sufficiently fast to allow detailed single beat whole-heart im-
aging during a short breath hold using ECG-gating. PET and 
MR image acquisition takes much longer than CT, amplifying 
the negative impact of cardiac and respiratory movement on 
image quality. Although ECG-gating combined with breath 
hold acquisition, or respiratory motion tracking, is possible, 
these strategies are inefficient, as only a fraction of the data 
can be used. Self-navigation approaches introduced for MRI 
can track and correct for cardiac motion more effectively, lead-
ing to better scanning efficiency with the potential to reduce 
scanning time, motion blurring, and improve image quality.206 
In principle, these methods could be applied to PET acquired 
simultaneously on hybrid PET/MR scanners, again improv-
ing efficiency and reducing radiation exposure. Alternatively, 
postprocessing methods for PET image motion correction 
include data-driven correction respiratory gating using defor-
mation fields generated from 4D PET,207 and cardiac motion 
frozen technique.208 Motion correction of gated 18F-NaF coro-
nary PET images is feasible and has been shown to reduce 
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noise and increase tissue-to-background ratio compared with 
ungated and single-bin data (Figure 8).208 Such advances will, 
in future, help to facilitate translation of atherosclerosis imag-
ing techniques on the horizon to routine clinical practice.
Conclusions and Future Directions
In a new era of precision, personalized medicine, the diag-
nostic power of current and emerging atherosclerosis imaging 
methods will undoubtedly influence our approach to patient 
care and help drive cardiovascular research in effort to bet-
ter understand disease mechanisms and test new treatments 
in the pipeline. With evolving technology and innovation, 
patient-specific multimodal imaging strategies can be tailored 
to reveal molecular signals with anatomic precision, while 
integrating data on plaque composition and local hemody-
namics with markers of overall disease burden—thus, moving 
away from a plaque-centric approach, toward greater appre-
ciation of the complexities underpinning the pathogenesis of 
atherosclerosis.
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